Soleno Therapeutics (SLNO) Operating Margin (2015 - 2026)

Soleno Therapeutics (SLNO) reported Operating Margin of 33.06% for Q1 2026, down 23.37% quarter-over-quarter from 43.15% in Q4 2025.

Soleno Therapeutics (SLNO) Operating Margin (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Operating Margin data on file, last reported at 33.06% in Q1 2026.

Operating Margin for Q1 2026 came in at 33.06%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 30.33% (changed N/A YoY), and the FY2025 annual result was 4.94%, changed N/A from the prior year.
Operating Margin declined to 33.06% in Q1 2026 per SLNO's latest filing, from 43.15% in the prior quarter.
Over five years, Operating Margin peaked at 43.15% in Q4 2025 and troughed at 19.98% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Soleno Therapeutics	2.76 Bn	2.51 Bn	93.41 Mn	33.06%

Download Data